We recently identified Kr|pple-like factor 7 (KLF17) as a negative regulator of epithelial-mesenchymal transition (EMT) using a genome-wide RNAi screen in mice. The human KLF17 gene is located at chromosome 1p34 where allelic loss of heterozygosity (LOH) correlates with poor prognosis in breast cancer. The overall goal of this proposal is to determine the molecular mechanisms and genetic regulation of transcription factor KLF17 in tumor maintenance and EMT, and determine the therapeutic value of KLF17 modulation and prognostic value of KLF17 in breast cancer. We will use molecular profiling, cellular assays and animal models to elucidate the mechanisms of KLF17 functions and regulation. We will proceed from the following aims:
Aim 1. Determine the molecular mechanisms of KLF17 regulation and function in tumor growth and EMT. We will determine the effect of Id2 and ARHGAP29, regulated by KLF17, individually and the combined effect of these two genes on tumor cell growth and EMT both in vitro and in mouse models. We will use in vitro assays and in vivo orthotopic transplantation mouse models to test their functions in tumor invasion and metastasis. Epistasis analysis will be performed to determine whether these genes are major mediators of KLF17 in tumor growth and EMT. We will also investigate the molecular mechanisms of KLF17 regulation by SNAI1 (Snail), a known EMT regulator, transcriptionally and by microRNA miR-129 post-transcriptionally. We will determine whether KLF17 is a direct target of SNAI1 and whether miR-129 directly targets KLF17 at its 3'UTR. The functions of SNAI1 and miR-129 in EMT and tumor invasion will be determined by in vitro assays and tumor xenograft mouse models. Epistasis analysis will be performed to determine whether KLF17 is a major mediator of SNAI1 and miR-129 in EMT and tumor invasion.
Aim 2. Characterize the function of KLF17 in tumor maintenance. We will use xenograft models and cells expressing KLF17 short hairpin RNA (shRNA) and Ras in an inducible vector to test whether modulation of KLF17 expression alone or in combination with Ras inhibition can cause tumor regression in breast cancer. We will investigate whether KLF17 knockdown antagonizes Ras-induced senescence in tumors using xenograft animal models and determine the pathways that KLF17 interferes with in Ras-induced senescence. These experiments will determine whether KLF17 alone or in combination with Ras can serve as a potential therapeutic target in the treatment of breast cancer.
Aim 3. Determine the prognostic value of KLF17, Id1, SNAI1 and miR-129 in clinical breast cancer samples. We will determine the expression of KLF17 and Id1, along with Snail and miR-129 in clinical primary breast cancer samples with known clinical outcomes to assess whether they can be used as prognostic markers for relapse in breast cancer.

Public Health Relevance

This proposal studies transcription factor KLF17 in tumor maintenance, epithelial- mesenchymal transition (EMT) and metastasis. Tumor spread from a primary site to distant sites is responsible for most cancer death. EMT plays a critical role in tumor spread. Currently there are few prognostic markers and therapeutics for metastatic disease. KLF17 was recently discovered in my laboratory to be involved in EMT by a genome-wide RNAi screen. Elucidation of the molecular mechanisms of KLF17 in EMT and metastasis will provide potential prognostic marker and therapeutics for the treatment of this deadly disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Ault, Grace S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Hu, Xiaowen; Feng, Yi; Zhang, Dongmei et al. (2014) A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell 26:344-57
Yu, Gan; Li, Heng; Wang, Ji et al. (2014) miRNA-34a suppresses cell proliferation and metastasis by targeting CD44 in human renal carcinoma cells. J Urol 192:1229-37
Gumireddy, Kiranmai; Li, Anping; Kossenkov, Andrew V et al. (2014) ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res 12:1334-43
Yu, Gan; Yao, Weimin; Gumireddy, Kiranmai et al. (2014) Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther 13:3086-97
Gumireddy, Kiranmai; Li, Anping; Yan, Jinchun et al. (2013) Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. EMBO J 32:2672-84
Gumireddy, Kiranmai; Li, Anping; Cao, Lili et al. (2013) NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis. J Carcinog Mutagen 2013:
Yan, Jinchun; Yang, Qin; Huang, Qihong (2013) Metastasis suppressor genes. Histol Histopathol 28:285-92
Chen, Jun; Sprouffske, Kathleen; Huang, Qihong et al. (2011) Solving the puzzle of metastasis: the evolution of cell migration in neoplasms. PLoS One 6:e17933